How Exosomes Are Tested: Questions to Ask Your Practitioner
Reviewed by ExaVeyra Sciences editorial team · Updated 12 October 2026
ExaVeyra Sciences is a Miami-based B2B supplier of exosomes for topical aesthetic use to licensed clinics, and it refers licensed prescribers to a 503A compounding pharmacy that prepares formulations against individual prescriptions.
| Question | Answer |
|---|---|
| What this is | The lab analysis behind an exosome lot, the documentation a careful supplier keeps, and the questions to ask your practitioner about their material. |
| Who can buy | Licensed clinics and practitioners, after ExaVeyra verifies an active professional license and NPI and, for exosome material, a signed professional-use acknowledgment. |
| What ships or is provided | Exosome formats for topical aesthetic use, characterized per lot, ship cold chain by overnight shipping, and arrival can take 1 to 3 business days. A certificate of analysis is issued for every lot and provided on request. |
Exosomes, the small biomolecular signaling vesicles that cells release, are an active area of research, and the material used in clinics comes from a growing number of suppliers. Two vials sold under the same word can differ in where the material came from, how it was characterized and how it was handled on the way to the clinic. Lab analysis is how those differences become visible.
This page is written for practitioners and for people considering a treatment at a clinic. It explains what testing can establish about a lot, and it lists the questions that tell you how carefully the material in a particular clinic was sourced.
Understanding the federal position
The FDA states that there are currently no FDA-approved exosome products. Exosome material reaches clinics under other frameworks, such as topical aesthetic use by licensed practitioners or laboratory research, and the quality of what arrives depends on the manufacturer and the supply chain behind it. That is the reason documentation matters: it is the record a practitioner can check.
What lab analysis establishes about a lot
A Certificate of Analysis (COA) is the summary of tests run on one specific lot. Read together, its sections answer four separate questions about the material.
| Question | What the lab measures | Where it is explained |
|---|---|---|
| Is it vesicle material? | Particle size and concentration, and the protein markers associated with extracellular vesicles | Particle counting and marker panel articles |
| How was it counted? | The instrument and method behind the particle figure, since results depend on the platform | Particle counting methods |
| Is it free of contamination? | Sterility, bacterial endotoxin and mycoplasma testing on the lot | Sterility, endotoxin and mycoplasma |
| Was it handled correctly? | Storage temperature, shipping conditions and receiving records | Cold chain validation |
The international reporting standard for this field, MISEV2023, sets out which characterization a study of vesicle material should report. It describes categories of evidence, such as particle measurements and protein markers, rather than a single pass mark, which is why the method behind each number matters as much as the number.
Questions to ask your practitioner
- Which manufacturer makes the exosome material used here, and who supplies it to the clinic?
- Is there a Certificate of Analysis for the lot used, and can the clinic see it?
- Which method was used to count the particles, and what did the lot measure?
- Was the lot tested for sterility, endotoxin and mycoplasma?
- How is the material stored at the clinic, and how did it arrive?
- Is each vial traceable to its lot, so a question about it can be answered later?
A practitioner who sources carefully can usually answer these quickly, because the answers come from records the supplier keeps. Questions are a normal part of choosing a clinic, and a good practice welcomes them.
How ExaVeyra documents the material it supplies
ExaVeyra supplies Kimera exosome material to licensed practices for topical aesthetic use by licensed practitioners. Every vial is traceable to its lot, the lot-specific Certificate of Analysis is available to the practice on request, and the material travels frozen in a documented cold chain. Practitioners can ask us for the lot documentation behind any order.
Sources
- FDA, Public Safety Notification on Exosome Products (accessed 12 October 2026)
- 21 CFR 610.12, Sterility (accessed 12 October 2026)
- 21 CFR Part 1271, human cells, tissues, and cellular and tissue-based products (accessed 12 October 2026)
Scientific literature
Each source carries the kind of study it was and, where the study enrolled people, how many. Study design decides what a result can establish, so it is stated rather than left to be inferred. Each line also says what that source is carrying on this page.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Consensus statementLandmarkSource 1 supports: The current reporting standard for vesicle research. Cited for the point that characterization is reported as categories of evidence rather than a single pass mark.
- Vestad B, Llorente A, Neurauter A, et al. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. Journal of Extracellular Vesicles, 2017. doi:10.1080/20013078.2017.1344087 PMID:28804597In vitroSource 2 supports: Variation within one counting method from settings and operator choices. Cited for why the method belongs next to the number on a certificate.
- Sivanantham A, Jin Y Impact of storage conditions on EV integrity, surface markers and cargos. Life, 2022. doi:10.3390/life12050697 PMID:35629364Narrative reviewSource 3 supports: A review of how storage affects vesicle integrity, surface markers and cargo. Cited for why receiving and storage records belong in the questions a buyer asks.